To allow countries, primarily in Asia and Africa, to continue rotavirus surveillance activities in anticipation of the introduction of the rotavirus vaccine.
Funding Partners:
GlaxoSmithKline Biologicals S.A.
Merck
Program Partners:
CDC's National Center for Immunization and Respiratory Diseases
